{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:25:08Z","timestamp":1783826708831,"version":"3.55.0"},"reference-count":31,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.3201\/eid2804.211961","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:26:28Z","timestamp":1647649588000},"page":"734-742","source":"Crossref","is-referenced-by-count":8,"title":["SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil"],"prefix":"10.3201","volume":"28","author":[{"given":"Daniel Gon\u00e7alves","family":"Chaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Hiroshi Caldeira","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Clara Fernandes","family":"da Silva Malta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Rocha","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edel Figueiredo","family":"Barbosa-Stancioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00edsa Aparecida","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Lobato","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2804.211961-202203171040-R1","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard [cited 2021 Sep 15]. https:\/\/covid19.who.int"},{"key":"key-10.3201\/eid2804.211961-202203171040-R2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.006","article-title":"Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study.","volume":"80","author":"Huang","year":"2020","journal-title":"J Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.","volume":"53","author":"Lai","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R4","doi-asserted-by":"publisher","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","article-title":"Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.","volume":"17","author":"Buitrago-Garcia","year":"2020","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2804.211961-202203171040-R5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/jmv.26353","article-title":"The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19.","volume":"93","author":"Zhou","year":"2021","journal-title":"J Med Virol"},{"key":"key-10.3201\/eid2804.211961-202203171040-R6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R7","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jinf.2020.04.019","article-title":"Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients.","volume":"81","author":"Lee","year":"2020","journal-title":"J Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R8","doi-asserted-by":"publisher","first-page":"104542","DOI":"10.1016\/j.jcv.2020.104542","article-title":"SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons.","volume":"130","author":"Wellinghausen","year":"2020","journal-title":"J Clin Virol"},{"key":"key-10.3201\/eid2804.211961-202203171040-R9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/cid\/ciaa1116","article-title":"Serosurveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence using global blood donor populations.","volume":"72","author":"Busch","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2804.211961-202203171040-R10","doi-asserted-by":"crossref","unstructured":"Kadkhoda K. Letter to the editor: COVID-19: how accurate are seroprevalence studies? Euro Surveill. 2020;25:2001374.","DOI":"10.2807\/1560-7917.ES.2020.25.30.2001374"},{"key":"key-10.3201\/eid2804.211961-202203171040-R11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1126\/science.abe9728","article-title":"Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.","volume":"371","author":"Buss","year":"2021","journal-title":"Science"},{"key":"key-10.3201\/eid2804.211961-202203171040-R12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.abb3221","article-title":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).","volume":"368","author":"Li","year":"2020","journal-title":"Science"},{"key":"key-10.3201\/eid2804.211961-202203171040-R13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0947-3580(99)70161-5","article-title":"Unknown input observers for uncertain systems: a unifying approach.","volume":"5","author":"Takahashi","year":"1999","journal-title":"Eur J Control"},{"key":"key-10.3201\/eid2804.211961-202203171040-R14","unstructured":"Centers for Disease Control and Prevention. COVID-19 forecasts: cases [cited 2021 Sep 15]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/forecasting\/forecasts-cases.html"},{"key":"key-10.3201\/eid2804.211961-202203171040-R15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1109\/TME.1964.4323124","article-title":"Observing the state of a linear system.","volume":"8","author":"Luenberger","year":"1964","journal-title":"IEEE Trans Mil Electron"},{"key":"key-10.3201\/eid2804.211961-202203171040-R16","doi-asserted-by":"publisher","first-page":"e00941","DOI":"10.1128\/JCM.00941-20","article-title":"Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho.","volume":"58","author":"Bryan","year":"2020","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2804.211961-202203171040-R17","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41467-020-18468-8","article-title":"SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.","volume":"11","author":"Ng","year":"2020","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2804.211961-202203171040-R18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tmrv.2021.07.003","article-title":"Progression and predictors of SARS-CoV-2 antibody seroreactivity in US blood donors.","volume":"35","author":"Vassallo","year":"2021","journal-title":"Transfus Med Rev"},{"key":"key-10.3201\/eid2804.211961-202203171040-R19","doi-asserted-by":"publisher","first-page":"ciab537","DOI":"10.1093\/cid\/ciab537","article-title":"Use of U.S. blood donors for national serosurveillance of SARS-CoV-2 antibodies: basis for an expanded national donor serosurveillance program.","author":"Stone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2804.211961-202203171040-R20","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1038\/s41467-020-19481-7","article-title":"Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.","volume":"11","author":"Slot","year":"2020","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2804.211961-202203171040-R21","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41467-021-21503-x","article-title":"The prevalence of antibodies to SARS-CoV-2 among blood donors in China.","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2804.211961-202203171040-R22","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2804.211961-202203171040-R23","unstructured":"Public Health England. Sero-surveillance of COVID-19 [cited 2021 Sep 15]. https:\/\/www.gov.uk\/government\/publications\/national-covid-19-surveillance-reports\/sero-surveillance-of-covid-19"},{"key":"key-10.3201\/eid2804.211961-202203171040-R24","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.jinf.2020.09.021","article-title":"Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening.","volume":"81","author":"Pagani","year":"2020","journal-title":"J Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R25","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1038\/s41467-021-25946-0","article-title":"SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.","volume":"12","author":"Nwosu","year":"2021","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid2804.211961-202203171040-R26","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1016\/S2214-109X(20)30387-9","article-title":"SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.","volume":"8","author":"Hallal","year":"2020","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid2804.211961-202203171040-R27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/cid\/ciaa849","article-title":"Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors.","volume":"72","author":"Erikstrup","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2804.211961-202203171040-R28","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jinf.2020.07.031","article-title":"Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay.","volume":"81","author":"Hamilton","year":"2020","journal-title":"J Infect"},{"key":"key-10.3201\/eid2804.211961-202203171040-R29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"key-10.3201\/eid2804.211961-202203171040-R30","doi-asserted-by":"publisher","first-page":"eabh3409","DOI":"10.1126\/sciadv.abh3409","article-title":"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay.","volume":"7","author":"Peluso","year":"2021","journal-title":"Sci Adv"},{"key":"key-10.3201\/eid2804.211961-202203171040-R31","unstructured":"National Health Surveillance Agency. Technical Note No. 13\/2020CGSH\/DAET\/SAES\/MS. Update of the technical criteria contained in Technical Note No. 5\/2020CGSH\/DAET\/SAES\/MS for clinical screening of blood donation candidates related to the risk of infection by SARSCoV2 (virus causing COVID19) [in Portuguese] [cited 2021 Dec 3]. http:\/\/antigo.anvisa.gov.br\/documents\/2857848\/5624592\/SEI_MS+-+0014052636+-+Nota+T%C3%A9cnica+13.pdf"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/4\/21-1961_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:55:26Z","timestamp":1732989326000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/4\/21-1961_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2804.211961","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}